Requires reporting of the tick-borne disease of Alpha-gal syndrome.
S10340 would amend the New York Public Health Law to add a new section requiring the state Department of Health to treat Alpha-gal syndrome as a reportable disease or condition. Alpha-gal syndrome is described in the bill as a serious, potentially life-threatening allergic condition triggered by a tick bite. Under the bill, the commissioner of health would be directed to adopt rules and regulations requiring health care practitioners and facilities to report diagnoses of Alpha-gal syndrome.
The bill also requires the Department of Health to include Alpha-gal syndrome in the tick-borne disease surveillance report prepared by the bureau of communicable disease control. In practical terms, this would place Alpha-gal syndrome within the state’s formal surveillance and reporting framework for tick-borne illnesses, allowing public health officials to track diagnoses more systematically and incorporate the condition into statewide monitoring efforts. The bill would take effect 180 days after becoming law.
The bill would amend the Public Health Law by creating a new reporting and surveillance requirement for Alpha-gal syndrome. It would affect health care practitioners, hospitals, and other facilities by obligating them to report diagnoses once the commissioner establishes the rules. It would also expand the Department of Health’s tick-borne disease surveillance reporting to include Alpha-gal syndrome, which could improve data collection, public health tracking, and awareness of the condition in New York.
There is no recorded committee transcript or vote history in the provided material, so no formal debate or vote-based sentiment can be identified. Based on the bill text alone, the measure appears to be framed as a public health and surveillance bill intended to improve reporting of a serious emerging condition. The overall tone is precautionary and supportive of state monitoring rather than regulatory restriction.
No specific points of contention are documented in the provided transcripts or voting history. Potential areas of concern, if raised in future debate, could include the reporting burden on clinicians and facilities, the scope of the commissioner’s rulemaking authority, and whether Alpha-gal syndrome should be treated as a reportable condition alongside other tick-borne diseases. However, none of those issues are attributed to any particular stakeholder in the available record.